Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models
- PMID: 12921513
- DOI: 10.1345/aph.1C199
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models
Abstract
Objective: To review in vitro and animal model studies with fluoroquinolones and the pharmacokinetic and pharmacodynamic relationships that are predictive of clinical and microbiologic outcomes and resistance. Data on fluoroquinolones are summarized and examine the premise that a single area under the inhibitory concentration-time curve (AUIC) target >125 may be used for all fluoroquinolones with concentration-dependent killing actions and against all target organisms.
Data sources: Primary articles were identified by MEDLINE search (1966-February 2002) and through secondary sources.
Study selection and data extraction: All of the articles identified from the data sources were evaluated, and all information deemed relevant was included.
Data synthesis: The fluoroquinolones exhibit concentration-dependent killing. This effect clearly depends on concentrations achieved, and outcomes depend on endpoints established by individual investigators. With AUIC values <60, the actions of fluoroquinolones are essentially bacteriostatic; any observed bacterial killing is the combined effect of low concentrations in relation to minimum inhibitory concentration and the action of host factors such as neutrophils and macrophages. AUIC values >100 but <250 yield bacterial killing at a slow rate, but usually by day 7 of treatment. AUICs >250 produce rapid killing, and bacterial eradication occurs within 24 hours. Disagreements regarding target endpoints are the expected consequences of comparing microbial and clinical outcomes across animal models, in vitro experiments, and humans when the endpoints are clearly not equivalent. Careful attention to time-related events, such as speed of bacterial killing, versus global endpoints, such as bacteriologic cure, allows optimal break points to be defined.
Conclusions: Evidence from in vitro and animal models favors the use of AUIC values >250 for rapid bactericidal action, regardless of whether the organism is gram-negative or gram-positive.
Comment in
-
Challenges in pharmacodynamic studies of antimicrobial resistance.Ann Pharmacother. 2003 Sep;37(9):1329-30. doi: 10.1345/aph.1D152. Ann Pharmacother. 2003. PMID: 12921518 No abstract available.
-
Fluoroquinolone AUIC break points and the link to bacterial killing rates: in vitro models.Ann Pharmacother. 2003 Sep;37(9):1331-4. doi: 10.1345/aph.1D095. Ann Pharmacother. 2003. PMID: 12921519 No abstract available.
Similar articles
-
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Ann Pharmacother. 2003 Oct;37(10):1478-88. doi: 10.1345/aph.1C419. Ann Pharmacother. 2003. PMID: 14519053 Review.
-
Fluoroquinolone AUIC break points and the link to bacterial killing rates: in vitro models.Ann Pharmacother. 2003 Sep;37(9):1331-4. doi: 10.1345/aph.1D095. Ann Pharmacother. 2003. PMID: 12921519 No abstract available.
-
In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.Semin Respir Infect. 1997 Dec;12(4):278-93. Semin Respir Infect. 1997. PMID: 9436955 Review.
-
Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S127-35. doi: 10.1086/428053. Clin Infect Dis. 2005. PMID: 15942879 Review.
-
Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia.Semin Respir Crit Care Med. 2006 Feb;27(1):51-67. doi: 10.1055/s-2006-933674. Semin Respir Crit Care Med. 2006. PMID: 16508882 Review.
Cited by
-
Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults.Antimicrob Agents Chemother. 2011 Jul;55(7):3240-3. doi: 10.1128/AAC.01680-10. Epub 2011 May 16. Antimicrob Agents Chemother. 2011. PMID: 21576432 Free PMC article. Clinical Trial.
-
Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus.Antimicrob Agents Chemother. 2011 May;55(5):2409-12. doi: 10.1128/AAC.00975-10. Epub 2011 Feb 22. Antimicrob Agents Chemother. 2011. PMID: 21343454 Free PMC article.
-
Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Antimicrob Agents Chemother. 2015 Jul;59(7):3800-7. doi: 10.1128/AAC.00341-15. Epub 2015 Apr 13. Antimicrob Agents Chemother. 2015. PMID: 25870068 Free PMC article.
-
Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.Antimicrob Agents Chemother. 2005 Oct;49(10):4234-9. doi: 10.1128/AAC.49.10.4234-4239.2005. Antimicrob Agents Chemother. 2005. PMID: 16189103 Free PMC article.
-
Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis.Open Forum Infect Dis. 2021 Dec 29;9(3):ofab660. doi: 10.1093/ofid/ofab660. eCollection 2022 Mar. Open Forum Infect Dis. 2021. PMID: 35146045 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources